2 weeks Ago By Moneycontrol
Prabhudas Lilladher's research report on Eris Lifesciences Eris Lifesciences’(ERIS) Q3FY25 EBITDA was in line with our estimate (Rs2.5bn; 43% YoY). Eris has opted for inorganic route to diversify and scale up existing portfolio.
This has been implemented without diluting margins. We expect margins to sustain at +35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based offerings in the derma segment, opportunities in the cardiometabolic market with patent expirations and benefits of operating leverage, as revenue scales up from these acquisitions.
Outlook Our FY26 and FY27E EBITDA broadly remains unchanged. We maintain ‘BUY’ rating with revised TP of Rs1,450 (valuing at 15x EV/EBITDA on FY27E). For all recommendations report, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.
com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Eris Lifesciences - 05022025 - prabhu.
